You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: OASIS PHARMACEUTICALS, LLC Topic: NCI
Hepatocellular carcinoma (HCC) has become the second leading cause of cancer-related death in the world, with a 72% mortality rate in the US. The rise in incidence of HCC is due to a steady increase in the major risk factors of liver fibrosis, cirrhosis, and hepatitis B/C, with limited efficacy conferred by existing treatments at advanced stages of the disease. Systemic therapy with tyrosine kinas ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: Up Therapeutics LLC Topic: NCI
Abstract. Glioblastoma (GBM) is an aggressive and deadly brain cancer with a one year median survival due to the lack of effective targeted treatments. Our goal is to develop a small molecule inhibitor targeting RPN13 protein in the 19S proteasome complex as a new drug for GBM. RPN13 is a proteasome ubiquitin receptor that recognizes ubiquitin-conjugated proteins that are thus tagged for degradati ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: PACDNA LLC Topic: NCI
Project Summary/AbstractMutant forms of KRAS are a key driver in human tumors but remain partially refractory to therapeutic intervention. After over three decades of research, only a single inhibitor (sotorasib) targeting a single mutation (KRASG12C) have reached market. The difficulty for developing small molecule KRAS inhibitors has heightened the importance of alternative methods targeting the ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: HOPEFUL AGING LLC Topic: NIA
PROJECT SUMMARY/ABSTRACTHealthcare systems around the world, including within the United States, have long-established shortages of trained caregivers (WHO, 2016; Jones, Liu, Murfield, andamp; Moyle, 2020). The American Health Care Association (2019) states that “the health care system has experienced a shortage of trained caregivers for critical roles for some time.” This scarcity directly im ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: ELITE ATHLETE PRODUCTS INC Topic: NICHD
PROJECT SUMMARY More than 795,000 individuals suffer from a stroke each year in the United States, making stroke a leading cause of adult disability in the United States and worldwide. More than half of stroke survivors exhibit reduced independence and functional mobility due to stroke-related gait impairments. Despite significant advancements in post-stroke medical care and rehabilitation, curren ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: GROW BIOMEDICINE LLC Topic: 300
Project Summary We have developed a candidate product that induces colon epithelial repair in ulcerative colitis (UC) models. UC comprises a major type of inflammatory bowel disease and is characterized by chronic and relapsing inflammation in the gastrointestinal (GI) tract. UC develops in the innermost mucosal layer of the distal GI tract in a continuous manner, usually starting at the rectum an ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: VENOVA TECHNOLOGIES, INC. Topic: NICHD
PROJECT SUMMARY The applicant, Venova Technologies, is a woman-led medical device startup company. Venova Technologies is applying for a Small Business Technology Transfer (STTR) Phase I grant to fund development towards technical milestones that will advance the commercial potential of our patent-pending non-hormonal contraceptive device. Half of pregnancies in the United States are unintended du ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
FASTT telehealth behavioral support service for caregivers of children with developmental delay or disabilitySBC: Special X, Inc Topic: NICHD
Project Abstract Over 7 million children in the U.S. receive support for a developmental delay or disability (DD). For caregivers of these children, behavior issues that often accompany their childandapos;s condition create high levels of stress leading to increased mental and physical health issues and impacts on caregiver-child interactions and family functioning. Although evidence-based practic ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
Development and Pre-Clinical Testing of Antimicrobial PEKK/Silicon Nitride Trauma Plates with Carbon Fiber ReinforcementSBC: SINTX TECHNOLOGIES, INC. Topic: NIAMS
PROJECT SUMMARY—More than 2 million Americans are hospitalized each year with bone fractures, and many more undergo outpatient procedures for fracture reduction and fixation. Some injuries can be treated with closed reduction and splinting or casting to immobilize the bone during healing. However, at some sites, more than half of fractures require open reduction and internal fixation. Despite ad ...STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
SBC: L2 DIAGNOSTICS LLC Topic: NIAID
ABSTRACTLyme disease, the most common vector-borne illness in North America, is caused by the spirochete B. burgdorferi. Infection begins in the skin following an infected tick-bite and acute illness is characterized by headache, fever and myalgia. Currently, there is no human vaccine against Lyme disease and therapeutic administration of antibiotics remains the recommended treatment option. In th ...STTR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health